Fracture risk in patients with different types of cancer

References

• Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int. 2005; 16: 707–711
   PubMed Web of Science ®Google Scholar
• Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br.J. Cancer 1999; 79: 1179–1181
   PubMed Web of Science ®Google Scholar
• Utz JP, Melton III LJ, Kan SH, Riggs BL. Risk of osteoporotic fractures in women with breast cancer: a population-based cohort study. J Chron Dis 1987; 40: 105–113
   PubMedGoogle Scholar
• Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 1996; 276: 1404–1408
   PubMed Web of Science ®Google Scholar
• Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21: 1215–1223
   PubMed Web of Science ®Google Scholar
• Kristensen B, Ejlertsen B, Mouridsen HT, Andersen KW, Lauritzen JB. Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res. Treat. 1996; 39: 321–326
   Google Scholar
• Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. British J Cancer 1990; 61: 308–310
   PubMed Web of Science ®Google Scholar
• Halton JM, Atkinson SA, Fraher L, Webber C, Gill GJ, Dawson S, et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J.Bone Miner. Res. 1996; 11: 1774–1783
   PubMed Web of Science ®Google Scholar
• Hogler W, Wehl G, van Staa T, Meister B, Klein-Franke A, Kropshofer G. Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research Database. Pediatr. Blood Cancer 2007; 48: 21–27
   PubMed Web of Science ®Google Scholar
• Mandel K, Atkinson S, Barr RD, Pencharz P. Skeletal morbidity in childhood acute lymphoblastic leukemia. J.Clin. Oncol. 2004; 22: 1215–1221
   PubMed Web of Science ®Google Scholar
• Wagner LM, Neel MD, Pappo AS, Merchant TE, Poquette CA, Rao BN, et al. Fractures in pediatric Ewing sarcoma. J.Pediatr.Hematol. Oncol. 2001; 23: 568–571
   PubMedGoogle Scholar
• Brown SA, Guise TA. Cancer-associated bone disease. Curr.Osteoporos. Rep. 2007; 5: 120–127
   PubMedGoogle Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 2006; 12: 6243s–6249s
   PubMed Web of Science ®Google Scholar
• Maduro JH, Pras E, Willemse PH, de Vries EG. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat. Rev. 2003; 29: 471–488
   PubMed Web of Science ®Google Scholar
• Wall JE, Kaste SC, Greenwald CA, Jenkins JJ, Douglass EC, Pratt CB. Fractures in children treated with radiotherapy for soft tissue sarcoma. Orthopedics 1996; 19: 657–664
   PubMedGoogle Scholar
• Theriault RL. Pathophysiology and implications of cancer treatment-induced bone loss. Oncology (Williston. Park) 2004; 18: 11–15
   PubMedGoogle Scholar
• van Leeuwen BL, Kamps WA, Jansen HW, Hoekstra HJ. The effect of chemotherapy on the growing skeleton. Cancer Treat. Rev. 2000; 26: 363–376
   PubMed Web of Science ®Google Scholar
• Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359: 2131–2139
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of morphine and opiates. J Intern Med 2006; 260: 76–87
   PubMed Web of Science ®Google Scholar
• Yoshida A, Nakamura Y, Shimizu A, Harada M, Kameda Y, Nagano A, et al. Significance of the parathyroid hormone-related protein expression in breast carcinoma. Breast Cancer 2000; 7: 215–220
   PubMedGoogle Scholar
• Atkins CD. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J.Natl. Cancer Inst. 2003; 95: 332–334
   PubMedGoogle Scholar
• Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N.Engl.J. Med. 1996; 334: 488–493
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br.J. Cancer 2004; 90: 1133–1137
   PubMed Web of Science ®Google Scholar
• Frank L. Epidemiology. When an entire country is a cohort. Science 2000; 287: 2398–2399
   PubMed Web of Science ®Google Scholar
• Andersen TF, Madsen M, Jørgensen J, Mellemkjær L, Olsen JH. The Danish National Hospital Register. Danish Medical Bulletin 1999; 46: 263–268
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: A nation-wide follow-up study in 16,416 patients in Denmark. Am J Epidemiol 2002; 156: 1–10
   PubMed Web of Science ®Google Scholar
• Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies. I. Principles. Am J Epidemiol 1992; 135: 1019–1028
   PubMed Web of Science ®Google Scholar
• Capella D. Descriptive tools and analysis. Drug Utilization Studies: Methods and Uses, MNG Dukes. WHO Regional Publications, European Series No. 45, Copenhagen 1993; 55–78
   Google Scholar
• Nielsen GL, Sørensen HT, Zhou W, Steffensen FH, Olsen J. The pharmaco-epidemiologic prescription database of North Jutland. Int J Risk Saf Med 1997; 10: 203–205
   PubMedGoogle Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Socioeconomic aspects of fractures within universal public healthcare: a nationwide case-control study from Denmark. Scand J Public Health 2006; 34: 371–377
   PubMed Web of Science ®Google Scholar
• Klotzbuecher CM, Ross PD, Landsman PB, Abbott III TA, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the litterature and statistical synthesis. J Bone Miner Res 2000; 15: 721–739
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic Acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif Tissue Int 2006; 79: 84–94
   PubMedGoogle Scholar
• van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Mineral Res 2000; 15: 993–1000
   PubMed Web of Science ®Google Scholar
• Munk-Jørgensen P, Mortensen PB. The Danish Psychiatric Central Register. Danish Medical Bulletin 1997; 44: 82–84
   PubMed Web of Science ®Google Scholar
• Miettinen OS. Theoretical epidemiology: Principles of occurrence research in medicine. Wiley & Sons, New York 1985; 1–359
   Google Scholar
• Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002; 94: 1867–1875
   PubMed Web of Science ®Google Scholar
• Grant WB. Ecologic studies of solar UV-B radiation and cancer mortality rates. Recent Results Cancer Res 2003; 164: 371–377
   PubMedGoogle Scholar
• Bischoff HA, Stähelin HB, Dick W, Akos R, Knecht M, Salis C, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003; 18: 343–351
   PubMed Web of Science ®Google Scholar
• Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. The Lancet 2007; 370: 657–666
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Mosekilde L. Fracture risk associated with smoking-a meta-analysis. J Intern Med 2003; 254: 572–583
   PubMedGoogle Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med 2005; 257: 374–384
   PubMed Web of Science ®Google Scholar
• Nishigaki Y, Ohsaki Y, Toyoshima E, Kikuchi K. Increased serum and urinary levels of a parathyroid hormone-related protein COOH terminus in non-small cell lung cancer patients. Clin Cancer Res. 1999; 5: 1473–1481
   PubMedGoogle Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 2006; 12: 6243s–6249s
   Google Scholar
• Diamond TH, Bucci J, Kersley JH, Aslan P, Lynch WB, Bryant C. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol. 2004; 172: 529–532
   PubMedGoogle Scholar
• Dickman PW, Adolfsson J, Astrom K, Steineck G. Hip fractures in men with prostate cancer treated with orchiectomy. J Urol. 2004; 172: 2208–2212
   PubMed Web of Science ®Google Scholar
• Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern. Med 2005; 165: 552–558
   PubMed Web of Science ®Google Scholar
• Adami HO, Zack M, Kressner U, Persson I, Berglund A, Naessen T, et al. Hip fractures in women with breast cancer. Am J Epidemiol. 1990; 132: 877–883
   PubMed Web of Science ®Google Scholar
• Lamont EB, Lauderdale DS. Low risk of hip fracture among elderly breast cancer survivors. Ann Epidemiol. 2003; 13: 698–703
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637–645
   PubMed Web of Science ®Google Scholar
• Hogler W, Wehl G, van Staa T, Meister B, Klein-Franke A, Kropshofer G. Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research Database. Pediatr. Blood Cancer 2007; 48: 21–27
   PubMed Web of Science ®Google Scholar